自 2017 年双特异性抗体 blinatumomab 获批用于治疗复发性急性淋巴细胞白血病以来，众多双特异性抗体构建体的开发在血液系统恶性肿瘤中得到了显着扩展。许多药物最近在淋巴瘤、白血病和多发性骨髓瘤治疗的各个阶段获得了美国食品药物管理局和欧洲药品管理局的批准。本次综述的目的是提供双特异性抗体治疗的概述，包括导致效应 T 细胞靶向肿瘤的机制-相关抗原、不同构建体的治疗适应症、功效、毒性和挑战。通过访问 PubMed 和 ClinicalTrials.gov 进行了文献检索。虽然 NHL、MM 和 ALL 的治疗取得了巨大成功，但在 AML 等血液系统恶性肿瘤方面，进展仍然有限。重要的是继续研究新的设计、肿瘤抗原靶点，并进一步完善目前批准的双特异性抗体在治疗顺序方面的适用范围。希望随着近年来获得的知识和这些疗法的爆炸式增长，血癌患者将在未来几年继续受益于这些治疗。

Since the approval of the bispecific antibody blinatumomab in 2017 for the treatment of acute lymphoblastic leukemia in relapse, the development of numerous bispecific antibody constructs has dramatically expanded in hematologic malignancies. Many have recently received Food Drug Administration and European Medicines Agency approvals in various stages of treatment for lymphomas, leukemias, and multiple myeloma.The purpose of this review is to provide an overview of bispecific antibody treatment including the mechanisms leading to effector T cells targeting tumor-associated antigens, the treatment indications, efficacies, toxicities, and challenges of the different constructs. A literature search was performed through access to PubMed and clinicaltrials.gov.While there has been substantial success in the treatment of NHL, MM, and ALL, there are still hematologic malignancies such as AML where there has been limited progress. It is important to continue to investigate new designs, tumor antigen targets, and further refine where current approved bispecific antibodies fit in terms of sequencing of therapy. Hopefully, with the knowledge gained in recent years and the explosion of these therapies, patients with blood cancers will continue to benefit from these treatments for years to come.